Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
SAN DIEGO, Oct. 26, 2017 -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus’ third quarter 2017 financial results will be released on Thursday, November 2, 2017 at 4:01 p.m. Eastern Time. Company management will host a conference call on Thursday, November 2, 2017, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 8498419. The live audio webcast can be accessed via the Investor Relations’ section of Apricus’ website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 30 days following the live call.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which we own worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com.
Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States. RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.
CONTACT:
Matthew Beck
[email protected]
The Trout Group
(646) 378-2933
